Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer

Leonardo Ferrari, Emilio Bajetta, Ettore Seregni, Antonia Martinetti, Nicoletta Zilembo, Cristina Noberasco, Roberto Buzzoni, Carlo Botti, Simonetta Massaron, Ettore Bichisao, Luigi Celio, Emilio Bombardieri

Research output: Contribution to journalArticle

Abstract

The aim of our study is to evaluate insulin-like growth factor (IGF) and IGF binding protein (IGFBP)-3 circulating levels in postmenopausal women treated with type I aromatase inhibitor formestane for breast cancer. Sixty- three patients at their first relapse entered the trial and were randomly given formestane at 250 mg or 500 mg i.m. fortnightly. Effects of the endocrine treatment on IGF-1 and IGFBP-3 were measured before and during therapy at scheduled times. IGF-1 and IGFBP-3 seems to slightly increase in both the dose groups, but only IGFBP-3 levels showed statistically significant fluctuation (baseline vs 4 weeks, p=0.01925; baseline vs 10 weeks, p=0.04537). These modifications are unlikely to be related to clinical status because they were observed both in responsive and unresponsive patients. This report demonstrates that hormonal treatments for breast cancer (particularly, aromatase inhibitor administration) can modify growth factor disposition to tumour.

Original languageEnglish
Pages (from-to)163-167
Number of pages5
JournalInternational Journal of Oncology
Volume11
Issue number1
Publication statusPublished - 1997

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Aromatase
Somatomedins
Breast Neoplasms
Aromatase Inhibitors
Intercellular Signaling Peptides and Proteins
Therapeutics
Recurrence
Neoplasms
formestane

Keywords

  • Aromatase inhibitor
  • Breast cancer
  • Hormonal treatment
  • Insulin-like growth factors
  • Postmenopause

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer. / Ferrari, Leonardo; Bajetta, Emilio; Seregni, Ettore; Martinetti, Antonia; Zilembo, Nicoletta; Noberasco, Cristina; Buzzoni, Roberto; Botti, Carlo; Massaron, Simonetta; Bichisao, Ettore; Celio, Luigi; Bombardieri, Emilio.

In: International Journal of Oncology, Vol. 11, No. 1, 1997, p. 163-167.

Research output: Contribution to journalArticle

Ferrari, Leonardo ; Bajetta, Emilio ; Seregni, Ettore ; Martinetti, Antonia ; Zilembo, Nicoletta ; Noberasco, Cristina ; Buzzoni, Roberto ; Botti, Carlo ; Massaron, Simonetta ; Bichisao, Ettore ; Celio, Luigi ; Bombardieri, Emilio. / Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer. In: International Journal of Oncology. 1997 ; Vol. 11, No. 1. pp. 163-167.
@article{6c92f64cb7c6450b9fddea2d09b813a0,
title = "Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer",
abstract = "The aim of our study is to evaluate insulin-like growth factor (IGF) and IGF binding protein (IGFBP)-3 circulating levels in postmenopausal women treated with type I aromatase inhibitor formestane for breast cancer. Sixty- three patients at their first relapse entered the trial and were randomly given formestane at 250 mg or 500 mg i.m. fortnightly. Effects of the endocrine treatment on IGF-1 and IGFBP-3 were measured before and during therapy at scheduled times. IGF-1 and IGFBP-3 seems to slightly increase in both the dose groups, but only IGFBP-3 levels showed statistically significant fluctuation (baseline vs 4 weeks, p=0.01925; baseline vs 10 weeks, p=0.04537). These modifications are unlikely to be related to clinical status because they were observed both in responsive and unresponsive patients. This report demonstrates that hormonal treatments for breast cancer (particularly, aromatase inhibitor administration) can modify growth factor disposition to tumour.",
keywords = "Aromatase inhibitor, Breast cancer, Hormonal treatment, Insulin-like growth factors, Postmenopause",
author = "Leonardo Ferrari and Emilio Bajetta and Ettore Seregni and Antonia Martinetti and Nicoletta Zilembo and Cristina Noberasco and Roberto Buzzoni and Carlo Botti and Simonetta Massaron and Ettore Bichisao and Luigi Celio and Emilio Bombardieri",
year = "1997",
language = "English",
volume = "11",
pages = "163--167",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer

AU - Ferrari, Leonardo

AU - Bajetta, Emilio

AU - Seregni, Ettore

AU - Martinetti, Antonia

AU - Zilembo, Nicoletta

AU - Noberasco, Cristina

AU - Buzzoni, Roberto

AU - Botti, Carlo

AU - Massaron, Simonetta

AU - Bichisao, Ettore

AU - Celio, Luigi

AU - Bombardieri, Emilio

PY - 1997

Y1 - 1997

N2 - The aim of our study is to evaluate insulin-like growth factor (IGF) and IGF binding protein (IGFBP)-3 circulating levels in postmenopausal women treated with type I aromatase inhibitor formestane for breast cancer. Sixty- three patients at their first relapse entered the trial and were randomly given formestane at 250 mg or 500 mg i.m. fortnightly. Effects of the endocrine treatment on IGF-1 and IGFBP-3 were measured before and during therapy at scheduled times. IGF-1 and IGFBP-3 seems to slightly increase in both the dose groups, but only IGFBP-3 levels showed statistically significant fluctuation (baseline vs 4 weeks, p=0.01925; baseline vs 10 weeks, p=0.04537). These modifications are unlikely to be related to clinical status because they were observed both in responsive and unresponsive patients. This report demonstrates that hormonal treatments for breast cancer (particularly, aromatase inhibitor administration) can modify growth factor disposition to tumour.

AB - The aim of our study is to evaluate insulin-like growth factor (IGF) and IGF binding protein (IGFBP)-3 circulating levels in postmenopausal women treated with type I aromatase inhibitor formestane for breast cancer. Sixty- three patients at their first relapse entered the trial and were randomly given formestane at 250 mg or 500 mg i.m. fortnightly. Effects of the endocrine treatment on IGF-1 and IGFBP-3 were measured before and during therapy at scheduled times. IGF-1 and IGFBP-3 seems to slightly increase in both the dose groups, but only IGFBP-3 levels showed statistically significant fluctuation (baseline vs 4 weeks, p=0.01925; baseline vs 10 weeks, p=0.04537). These modifications are unlikely to be related to clinical status because they were observed both in responsive and unresponsive patients. This report demonstrates that hormonal treatments for breast cancer (particularly, aromatase inhibitor administration) can modify growth factor disposition to tumour.

KW - Aromatase inhibitor

KW - Breast cancer

KW - Hormonal treatment

KW - Insulin-like growth factors

KW - Postmenopause

UR - http://www.scopus.com/inward/record.url?scp=8544237726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544237726&partnerID=8YFLogxK

M3 - Article

C2 - 21528196

AN - SCOPUS:8544237726

VL - 11

SP - 163

EP - 167

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -